DOB: 10.10.2002
Patient ID: 1922998
ACC/AHA Risk Score:
Patient Info:
Gender: M
Fasting: No
BMI:
Test Name
Provider
Patient
Name: GARCIA, JACOB
Provider: ELAINE KING MD
16405 Sand Canyon Ave Ste 265
Irvine, CA 92618
Account No: 9786
Test Result
Specimen
FINAL REPORT
Accession No: C0136069
Requisition No:
Report Date & Time: 08.21.2020 1:45 PM
Received Date & Time: 08.20.2020 3:14 PM
Collection Date & Time: 08.19.2020 01:00 PM
Interpretation
Footnotes
Infectious Disease Tests
TaqPath COVID-19 NP SWAB
9
Notes
Not Detected
A not detected (negative) test result for this test means that SARS- CoV-2 RNA
was not present in the specimen above the limit of detection. Laboratory test
results should always be considered in the context of clinical observations and
epidemiological data in making a final diagnosis and patient management
decisions. Results will be reported to government agencies as required.
Specimen: Acceptable
This patient is under 18 years of age. Reference ranges are based on ages 18 years and older. Therefore, we recommend caution in clinical interpretation.
CLIA# 22D2100622
BHD-REP-003.03
NYSDOH: 9021
200 Crossing Blvd.
Framingham, MA 01702, 508.877.8711
Ernst J. Schaefer, MD
Laboratory Director / Chief Medical Officer
Page 1 of 3
Patient ID: 1922998
Gender: M
Test Name
Infectious Disease Tests
NYSDOH: 9021
Account No: 9786
Accession No: C0136069
Report Date & Time: 08.21.2020 1:45 PM
08.21.2020
(Current)
TaqPath COVID-19 NP SWAB
CLIA# 22D2100622
BHD-REP-003.03
Provider: ELAINE KING MD
Specimen
Name: GARCIA, JACOB
Provider
Patient
FINAL REPORT
-
200 Crossing Blvd.
Framingham, MA 01702, 508.877.8711
Ernst J. Schaefer, MD
Laboratory Director / Chief Medical Officer
Page 2 of 3
Patient ID: 1922998
Gender: M
Provider: ELAINE KING MD
Account No: 9786
Specimen
Name: GARCIA, JACOB
Provider
Patient
FINAL REPORT
Accession No: C0136069
Report Date & Time: 08.21.2020 1:45 PM
Notes
Boston Heart has not verified the reference ranges for the pediatric population. Use clinical discretion when interpreting results.
Footnotes
The intended use of this report is to provide an aid in the physician's treatment decisions. This report is intended for a physician or other qualified health care provider. Please consult
with your physician regarding any questions.
9This test has been validated by Boston Heart Diagnostics but FDA's independent review of the validation is pending. This test is performed as a laboratory developed test;
independent review of the validation under the FDA's Emergency Use Authorization authority (EUA # 200659) will be performed according to current guidance requirements. We will
continue to follow federal and state requirements for both notification of results and any confirmatory testing that is required by another agency. This test was developed and its
performance characteristics determined by Boston Heart Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. Results should be used in
conjunction with clinical findings and should not form the sole basis for a diagnosis or treatment decision. Methods: TaqPath COVID-19 NP SWAB: TaqPath SARS-CoV-2 Multiplex RTPCR Assay IVD
* Tests performed with alternative methodologies are not displayed for comparative purposes.
= Critical Value, = Alert Value, TNP = Test Not Performed, PEND = Test Result Pending, GSP = Glycated Serum Protein, ADA = American Diabetes Association
©2020 Boston Heart Diagnostics Corporation. All rights reserved. The Boston Heart Diagnostics logo, Boston Heart HDL Map, Boston Heart Cholesterol Balance, Boston Heart Prediabetes Assessment, and Boston Heart Fatty Acid
Balance are trademarks or registered trademarks of Boston Heart Diagnostics Corporation. TaqMan® is a registered trademark of Roche Molecular Systems, Inc.
CLIA# 22D2100622
BHD-REP-003.03
NYSDOH: 9021
200 Crossing Blvd.
Framingham, MA 01702, 508.877.8711
Ernst J. Schaefer, MD
Laboratory Director / Chief Medical Officer
Page 3 of 3